• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640428)   Today's Articles (1841)   Subscriber (50387)
For: Yano S, Yamaguchi M, Dong RP. EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy. Nihon Yakurigaku Zasshi 2003;122:491-7. [PMID: 14639003 DOI: 10.1254/fpj.122.491] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Number Cited by Other Article(s)
1
Kumar S, Ali I, Abbas F, Khan N, Gupta MK, Garg M, Kumar S, Kumar D. In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies. In Silico Pharmacol 2023;11:20. [PMID: 37575679 PMCID: PMC10412522 DOI: 10.1007/s40203-023-00157-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Accepted: 07/26/2023] [Indexed: 08/15/2023]  Open
2
The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare. Cancers (Basel) 2022;14:cancers14143511. [PMID: 35884570 PMCID: PMC9320221 DOI: 10.3390/cancers14143511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 07/14/2022] [Accepted: 07/16/2022] [Indexed: 02/05/2023]  Open
3
Gómez-Ganau S, Castillo J, Cervantes A, de Julián-Ortiz JV, Gozalbes R. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors. Curr Top Med Chem 2020;20:1628-1639. [PMID: 32493189 DOI: 10.2174/1568026620666200603122726] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 02/15/2020] [Accepted: 02/20/2020] [Indexed: 11/22/2022]
4
Lee YJ, Kim SY, Lee C. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells. Mol Med Rep 2019;19:3230-3236. [PMID: 30816529 DOI: 10.3892/mmr.2019.9957] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Accepted: 02/07/2019] [Indexed: 11/06/2022]  Open
5
Zou C, Li W, Pan Y, Khan ZA, Li J, Wu X, Wang Y, Deng L, Liang G, Zhao Y. 11β-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity. Oncotarget 2017;8:96263-96275. [PMID: 29221204 PMCID: PMC5707098 DOI: 10.18632/oncotarget.22015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 09/20/2017] [Indexed: 12/20/2022]  Open
6
Cagle PT, Allen TC. Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 2013. [PMID: 23194040 DOI: 10.5858/arpa.2012-0508-ra] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
7
Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res 2013;119:191-419. [PMID: 23870513 DOI: 10.1016/b978-0-12-407190-2.00016-2] [Citation(s) in RCA: 138] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
8
Filosso PL, Sandri A, Oliaro A, Filippi AR, Cassinis MC, Ricardi U, Lausi PO, Asioli S, Ruffini E. Emerging treatment options in the management of non-small cell lung cancer. LUNG CANCER-TARGETS AND THERAPY 2011;2:11-28. [PMID: 28210115 DOI: 10.2147/lctt.s8618] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
9
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009;63:1-9. [DOI: 10.1016/j.lungcan.2008.05.015] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2008] [Revised: 05/09/2008] [Accepted: 05/13/2008] [Indexed: 12/22/2022]
10
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 2008;31:329-34. [PMID: 18845990 DOI: 10.1097/coc.0b013e318161dc04] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
11
Jia Y, Gu XJ, Brinker A, Warmuth M. Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert Opin Drug Discov 2008;3:959-78. [DOI: 10.1517/17460441.3.8.959] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
12
Rehn AP, Cerny R, Sugars RV, Kaukua N, Wendel M. Osteoadherin is upregulated by mature osteoblasts and enhances their in vitro differentiation and mineralization. Calcif Tissue Int 2008;82:454-64. [PMID: 18496725 DOI: 10.1007/s00223-008-9138-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2008] [Accepted: 04/22/2008] [Indexed: 12/01/2022]
13
Nishi N, Kawai S, Yonezawa T, Fujimoto K, Masui K. Effect of gefitinib on brain metastases from non-small cell lung cancer. Neurol Med Chir (Tokyo) 2006;46:504-7. [PMID: 17062991 DOI: 10.2176/nmc.46.504] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
14
Jimeno A, Kulesza P, Kincaid E, Bouaroud N, Chan A, Forastiere A, Brahmer J, Clark DP, Hidalgo M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 2006;66:2385-90. [PMID: 16489045 DOI: 10.1158/0008-5472.can-05-2882] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA